GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kissei Pharmaceutical Co Ltd (TSE:4547) » Definitions » 3-Year EPS without NRI Growth Rate

Kissei Pharmaceutical Co (TSE:4547) 3-Year EPS without NRI Growth Rate : 29.30% (As of Dec. 2023)


View and export this data going back to 1988. Start your Free Trial

What is Kissei Pharmaceutical Co 3-Year EPS without NRI Growth Rate?

Kissei Pharmaceutical Co's EPS without NRI for the three months ended in Dec. 2023 was 円43.42.

During the past 12 months, Kissei Pharmaceutical Co's average EPS without NRI Growth Rate was 1311.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 29.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -24.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was -24.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Kissei Pharmaceutical Co was 56.70% per year. The lowest was -68.10% per year. And the median was 5.80% per year.


Competitive Comparison of Kissei Pharmaceutical Co's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Kissei Pharmaceutical Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kissei Pharmaceutical Co's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kissei Pharmaceutical Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Kissei Pharmaceutical Co's 3-Year EPS without NRI Growth Rate falls into.



Kissei Pharmaceutical Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Kissei Pharmaceutical Co  (TSE:4547) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Kissei Pharmaceutical Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Kissei Pharmaceutical Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Kissei Pharmaceutical Co (TSE:4547) Business Description

Traded in Other Exchanges
Address
19-48, Yoshino, Matsumoto City, Nagano, JPN, 399-8710
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kissei Pharmaceutical Co (TSE:4547) Headlines

No Headlines